Before matching, patients in the BRCA1/2 mutation group were more likely to have family history of ovarian cancer (P < 0.001), HER2-negative disease (P < 0.001), receive less anti-HER2 therapy (P = 0.001), and undergo more anthracycline followed by taxane regimens (P = 0.005) and carboplatin-containing regimens (P = 0.033) compared to those in the wild-type group. The gene discussed is BRCA1; the disease is ovarian carcinoma.